My ePortfolio Register   

Immunosuppressive therapy in myelodysplastic syndrome

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.12.17
Views: 747

Dr Maximilian Stahl - Yale Cancer Center, New Haven, USA

Dr Stahl speaks with ecancer at the 2017 ASH annual meeting about the use of immunosuppressive therapy in patients with the myelodysplastic syndromes. 

He outlines biomarkers assessed in the hopes of finding predictive factors for patient response, noting that only SF3B1 mutations were validated, negatively affecting response to IST.

Dr Stahl also describes differences in overall survival for patients achieving an objective response.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence